Skip to Main Content

Apellis Pharmaceuticals said Thursday that submission of additional clinical data to the Food and Drug Administration will delay the review of its experimental treatment for geographic atrophy — a chronic eye disease and a leading cause of blindness in older people.

The FDA was set to announce an approval decision for the Apellis drug on Nov. 26. The review will now be extended by three months to February 2023.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment